| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Division of Life Sciences (Dr. Zakzanis), University of Toronto; and Centre for Addiction and Mental Health (Dr. Young), Archway Clinic, Toronto, Ontario, Canada.
Address correspondence and reprint requests to Dr. Konstantine K. Zakzanis, University of Toronto at Scarborough, Division of Life Sciences (Neuroscience), 1265 Military Trail, Toronto, Ontario, M1C 1A4 Canada; e-mail: zakzanis{at}scar.utoronto.ca
To examine the neurotoxic potential of continued MDMA ("Ecstasy") use in humans and its functional consequences over the course of 1 year, 15 MDMA users participated in a longitudinal study in which they completed a brief neuropsychological test battery composed mainly of retrospective and prospective memory tasks. Subjects were abstinent for 2 weeks on initial and 1-year testing. Continued use of MDMA was associated with progressive decline in terms of immediate and delayed recall.
This article has been cited by other articles:
|
|
 |
|
  F Indlekofer, M Piechatzek, M Daamen, C Glasmacher, R Lieb, H Pfister, O Tucha, K. Lange, H. Wittchen, and C. Schutz Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol J Psychopharmacol, July 1, 2009; 23(5): 495 - 509. [Abstract] [PDF]
|
|
|
|
 |
|
 C. L. Busceti, F. Biagioni, B. Riozzi, G. Battaglia, M. Storto, C. Cinque, G. Molinaro, R. Gradini, A. Caricasole, A. M. Canudas, et al. Enhanced Tau Phosphorylation in the Hippocampus of Mice Treated with 3,4-Methylenedioxymethamphetamine ("Ecstasy") J. Neurosci., March 19, 2008; 28(12): 3234 - 3245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Schilt, M. M. L. de Win, M. Koeter, G. Jager, D. J. Korf, W. van den Brink, and B. Schmand Cognition in Novice Ecstasy Users With Minimal Exposure to Other Drugs: A Prospective Cohort Study Arch Gen Psychiatry, June 1, 2007; 64(6): 728 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Zakzanis and Z. Campbell Memory impairment in now abstinent MDMA users and continued users: A longitudinal follow-up Neurology, March 14, 2006; 66(5): 740 - 741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Parrott MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress J Psychopharmacol, March 1, 2006; 20(2): 147 - 163. [Abstract] [PDF]
|
|
|
|
|
|
J. Daumann, B. Till, T. Fischermann, M. Rezk, and E. Gouzoulis-Mayfrank Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study J Psychopharmacol, March 1, 2006; 20(2): 236 - 244. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Kouimtsidis, F. Schifano, T. Sharp, L. Ford, J. Robinson, and C. Magee Neurological and Psychopathological Sequelae Associated With a Lifetime Intake of 40,000 Ecstasy Tablets Psychosomatics, February 1, 2006; 47(1): 86 - 87. [Full Text] [PDF]
|
|
|
|
|
|
A. C. Parrott Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy J Psychopharmacol, January 1, 2005; 19(1): 71 - 83. [Abstract] [PDF]
|
|
|
|
 |
|
 L. A. Badon, A. Hicks, K. Lord, B. A. Ogden, S. Meleg-Smith, and K. J. Varner Changes in Cardiovascular Responsiveness and Cardiotoxicity Elicited during Binge Administration of Ecstasy J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 898 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. O'Keefe AAP supports campaign against club drugs AAP News, October 1, 2001; 19(4): 137 - 146. [Full Text] [PDF]
|
|
|
|
|
|
U. D. McCann, G. A. Ricaurte, and M. E. Molliver "Ecstasy" and Serotonin Neurotoxicity: New Findings Raise More Questions Arch Gen Psychiatry, October 1, 2001; 58(10): 907 - 908. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
